4Q Revenues: $130.5 million (+155%)
4Q Loss: $63.4 million (loss of $13.1 million 4Q11)
FY Revenues: $390.0 million (+109%)
FY Loss: $113.7 million (loss of $45.5 million FY11)
Comments: Manufacturing and royalty revenues were $326.4 million for the year (+108%). Product sales were $41.2 million (+43%), and R&D revenue was $22.3 million compared to $880,000 FY11. Growth in the quarter and FY reflects the Elan Drug Technologies merger. Results include a charge of $45.8 million related to in-process R&D acquired in the merger.